IMGN-151

Antibody–drug conjugate

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity
NCT07024784 · AbbVie
2025-07-30 – 2028-02 · Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)
What this study did
Phase 1 (1)
Endometrial Cancer
NCT05527184 · AbbVie
2023-01-11 – 2027-02 · Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Endometrial Cancer: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IMGN-151: this drugPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
DostarlimabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signal
NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023).
Fruquintinib (Fruzaqla / Elunate)Phase 3Small moleculeVEGFR1/2/3not yet gradedNo reviewed efficacy summary in this indication
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 3Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 3Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SelinexorPhase 3Small moleculeXPO1 (exportin-1)not yet gradedNo reviewed efficacy summary in this indication
Sofetabart Mipitecan
Phase 3(overall)
Antibody–drug conjugateFolate receptor alpha (FRα)
not yet graded(overall)
No reviewed efficacy summary in this indication
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Torvutatug Samrotecan
Phase 3(overall)
Antibody–drug conjugateFolate receptor alpha (FRα)
not yet graded(overall)
No reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
SerabelisibPhase 2Small moleculePI3K alpha (inhibitor)Weak signalNo reviewed efficacy summary in this indication
ABBV-901
Phase 1(overall)
UndisclosedFolate receptor alpha (FRα)
not yet graded(overall)
No reviewed efficacy summary in this indication
Luveltamab Tazevibulin
Discontinued
Antibody–drug conjugateFolate receptor alpha (FRα)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IMGN-151 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 1Endometrial CancerActive not recruiting
Est. primary completion 2027-02 · NCT05527184 · CT.gov ↗
What to watch
2028 (1)
January 2028 (1)
Phase 2Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)Recruiting
Est. primary completion 2028-01 · NCT07024784 · CT.gov ↗
What to watch

See the full readout calendar ↗